Gain Therapeutics (GANX) Short Interest Ratio & Short Volume → What President Biden's new law means for investors (From Stansberry Research) (Ad) Free GANX Stock Alerts $2.61 -0.02 (-0.76%) (As of 10:14 AM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Gain Therapeutics Short Interest DataCurrent Short Interest154,200 sharesPrevious Short Interest149,600 sharesChange Vs. Previous Month+3.07%Dollar Volume Sold Short$451,806.00Short Interest Ratio1.0 Days to CoverLast Record DateApril 30, 2024Outstanding Shares18,050,000 sharesFloat Size15,090,000 sharesShort Percent of Float1.02%Today's Trading Volume8,593 sharesAverage Trading Volume147,836 sharesToday's Volume Vs. Average6% Short Selling Gain Therapeutics ? Sign up to receive the latest short interest report for Gain Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGANX Short Interest Over TimeGANX Days to Cover Over TimeGANX Percentage of Float Shorted Over Time Ad Stansberry ResearchWhat President Biden's new law means for investorsWhat's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.This expert just went public with all the details, including which stocks to jump on immediately. Gain Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024154,200 shares $451,806.00 +3.1%1.0%1 $2.93 4/15/2024149,600 shares $462,264.00 +8.3%1.1%0.9 $3.09 3/31/2024138,100 shares $520,637.00 -11.9%1.0%0.9 $3.77 3/15/2024156,700 shares $672,243.00 +16.4%0.9%0.9 $4.29 2/29/2024134,600 shares $604,354.00 -2.2%0.8%0.8 $4.49 2/15/2024137,600 shares $660,480.00 +13.4%0.8%0.9 $4.80 Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024121,300 shares $469,431.00 +17.2%0.7%0.8 $3.87 1/15/2024103,500 shares $361,215.00 +66.1%0.6%1.2 $3.49 12/31/202362,300 shares $203,409.50 -42.0%0.4%0.7 $3.27 12/15/2023107,400 shares $268,500.00 -25.0%0.6%1.6 $2.50 11/30/2023143,200 shares $306,448.00 -18.9%1.2%2.4 $2.14 11/15/2023176,500 shares $511,850.00 -3.2%1.7%3.8 $2.90 10/31/2023182,400 shares $521,664.00 -9.5%1.8%4.9 $2.86 10/15/2023201,600 shares $665,280.00 +6.4%2.0%4.8 $3.30 9/30/2023189,500 shares $621,560.00 +5.2%1.9%4.5 $3.28 9/15/2023180,100 shares $666,370.00 +14.1%1.8%5.5 $3.70 8/31/2023157,900 shares $522,649.00 -6.4%1.6%4.5 $3.31 8/15/2023168,600 shares $606,960.00 +61.5%1.7%4.3 $3.60 7/31/2023104,400 shares $414,468.00 +66.0%1.1%2.3 $3.97 7/15/202362,900 shares $279,276.00 -6.5%0.7%0.9 $4.44 6/30/202367,300 shares $301,504.00 +21.7%0.7%1 $4.48 6/15/202355,300 shares $269,311.00 +24.8%0.6%0.8 $4.87 5/31/202344,300 shares $204,223.00 -19.6%0.5%0.5 $4.61 5/15/202355,100 shares $279,908.00 -7.9%0.6%0.7 $5.08 4/30/202359,800 shares $300,794.00 -7.1%0.7%0.8 $5.03 4/15/202364,400 shares $308,476.00 +7.3%0.7%0.9 $4.79 3/31/202360,000 shares $289,200.00 +20.2%0.7%1.1 $4.82 3/15/202349,900 shares $220,558.00 +64.1%0.6%0.9 $4.42 2/28/202330,400 shares $126,464.00 +35.7%0.3%0.7 $4.16 2/15/202322,400 shares $87,360.00 -16.7%0.3%0.5 $3.90 1/31/202326,900 shares $106,255.00 +45.4%0.3%0.7 $3.95 1/15/202318,500 shares $71,783.70 -70.5%0.2%0.5 $3.88 12/30/202262,700 shares $196,251.00 -10.7%0.6%1.9 $3.13 12/15/202270,200 shares $210,600.00 +146.3%0.7%2.3 $3.00 11/30/202228,500 shares $86,640.00 -25.4%0.3%1 $3.04 11/15/202238,200 shares $119,184.00 -21.1%0.4%1.2 $3.12 10/31/202248,400 shares $161,656.00 +6.6%0.5%1.4 $3.34 10/15/202245,400 shares $143,010.00 -30.3%0.5%1.2 $3.15 9/30/202265,100 shares $212,226.00 +50.0%0.8%1.5 $3.26 9/15/202243,400 shares $169,260.00 +80.8%0.6%1 $3.90Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some 8/31/202224,000 shares $82,800.00 -35.0%0.3%0.5 $3.45 8/15/202236,900 shares $153,135.00 -27.8%0.5%0.7 $4.15 7/31/202251,100 shares $203,378.00 +29.4%0.7%0.7 $3.98 7/15/202239,500 shares $158,395.00 -17.9%0.5%0.5 $4.01 6/30/202248,100 shares $173,160.00 -30.9%0.6%0.3 $3.60 6/15/202269,600 shares $224,808.00 +18.2%0.9%0.4 $3.23 5/31/202258,900 shares $175,522.00 -24.6%0.8%0.4 $2.98 5/15/202278,100 shares $208,527.00 +125.1%1.0%0.5 $2.67 4/30/202234,700 shares $118,674.00 -4.9%0.5%0.2 $3.42 4/15/202236,500 shares $140,160.00 No Change0.5%0.3 $3.84 3/31/202236,500 shares $149,285.00 +18.5%0.5%0.6 $4.09 3/15/202230,800 shares $103,180.00 -17.9%0.4%0.6 $3.35 2/28/202237,500 shares $138,375.00 -42.0%0.5%0.7 $3.69 2/15/202264,700 shares $270,446.00 +100.3%0.8%1.1 $4.18 1/31/202232,300 shares $129,200.00 -8.0%0.4%0.4 $4.00 1/15/202235,100 shares $164,268.00 +30.0%0.5%0.4 $4.68 12/31/202127,000 shares $146,610.00 -25.4%0.4%0.4 $5.43 12/15/202136,200 shares $204,530.00 -14.6%0.5%0.5 $5.65 11/30/202142,400 shares $306,976.00 +74.5%0.6%0.5 $7.24 11/15/202124,300 shares $208,008.00 +35.0%0.3%0.1 $8.56 10/29/202118,000 shares $125,280.00 -23.7%0.2%0.1 $6.96 10/15/202123,600 shares $163,784.00 -5.2%0.3%0.2 $6.94 9/30/202124,900 shares $185,505.00 -63.5%0.3%0.2 $7.45 9/15/202168,200 shares $543,554.00 +170.6%0.9%0.5 $7.97 8/31/202125,200 shares $196,560.00 -42.1%0.3%0.2 $7.80 8/13/202143,500 shares $348,000.00 No Change0.6%1.6 $8.00 GANX Short Interest - Frequently Asked Questions What is Gain Therapeutics' current short interest? Short interest is the volume of Gain Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 154,200 shares of GANX short. 1.02% of Gain Therapeutics' shares are currently sold short. Learn More on Gain Therapeutics' current short interest. What is a good short interest ratio for Gain Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GANX shares currently have a short interest ratio of 1.0. Learn More on Gain Therapeutics's short interest ratio. What is a good short interest percentage for Gain Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.02% of Gain Therapeutics' floating shares are currently sold short. Is Gain Therapeutics' short interest increasing or decreasing? Gain Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 154,200 shares, an increase of 3.1% from the previous total of 149,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Gain Therapeutics' float size? Gain Therapeutics currently has issued a total of 18,050,000 shares. Some of Gain Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gain Therapeutics currently has a public float of 15,090,000 shares. How does Gain Therapeutics' short interest compare to its competitors? 1.02% of Gain Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Gain Therapeutics: Eyenovia, Inc. (11.45%), CASI Pharmaceuticals, Inc. (0.73%), VYNE Therapeutics Inc. (0.68%), Unicycive Therapeutics, Inc. (2.13%), HCW Biologics Inc. (0.05%), Ocuphire Pharma, Inc. (4.71%), Xilio Therapeutics, Inc. (5.24%), NextCure, Inc. (0.53%), Lexaria Bioscience Corp. (2.29%), Cara Therapeutics, Inc. (5.62%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Gain Therapeutics stock? Short selling GANX is an investing strategy that aims to generate trading profit from Gain Therapeutics as its price is falling. GANX shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gain Therapeutics? A short squeeze for Gain Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GANX, which in turn drives the price of the stock up even further. How often is Gain Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GANX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: EYEN Short Squeeze CASI Short Squeeze VYNE Short Squeeze UNCY Short Squeeze HCWB Short Squeeze OCUP Short Squeeze XLO Short Squeeze NXTC Short Squeeze LEXX Short Squeeze CARA Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GANX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press